RESUMO
Corona virus disease 2019(COVID-19) is one of the most serious respiratory pandemic diseases threatening human health for centuries. Alopecia areata (AA) is a sudden patchy hair loss, an autoimmune disease, which seriously affects the image and mental health of patients. Evidence shows that the risk of autoimmune diseases significantly increases after COVID-19, and is positively correlated with the severity, with a significant increase in the risk of alopecia in those over 40 years old. The relationship between COVID-19 and AA has become a hot topic of current research. Strengthening the research on the correlation between COVID-19 and AA can help to identify and protect susceptible populations at an early stage. This article reviews the research progress on the epidemiological background of COVID-19 and AA, the situation and possible mechanisms of AA induced by COVID-19 or COVID-19 vaccination, and potential treatment methods.
Assuntos
Alopecia em Áreas , COVID-19 , SARS-CoV-2 , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/imunologia , Humanos , COVID-19/imunologia , COVID-19/epidemiologia , SARS-CoV-2/imunologia , Vacinas contra COVID-19/imunologiaRESUMO
Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring hair loss. Data are lacking on the epidemiology and clinical and economic burden of AA in Spain. To estimate the prevalence and incidence of AA in Spain and describe sociodemographic and clinical characteristics, treatment patterns, healthcare resource utilization (HCRU) and associated costs. This was an observational, retrospective, descriptive study based on the Health Improvement Network (THIN®) database (Cegedim Health Data, Spain). Patients with ICD9-Code 704.01 for AA, registered between 2014 and 2021, were identified. Prevalence (%) and incidence rates per 1,000 patient-years (IR) of AA were calculated and clinical characteristics, treatment characteristics and HCRU/costs were assessed. A total of 5,488 patients with AA were identified. The point prevalence of AA in 2021 was 0.44 (95% confidence interval [CI]: 0.43-0.45) overall, 0.48 (0.47-0.49) in adults, and 0.23 (0.21-0.26) in children ≤12 years. The 2021 IR for AA in adults was 0.55 (0.51-0.60). Of 3,351 adults with AA, 53.4% were female, mean (standard deviation [SD]) age was 43.1 (14.7) years, and 41.6% experienced comorbidities. Among adults, 2.7% used systemic treatment (0.5% immunosuppressants, 2.5% oral corticosteroids, 0.3% both). Laboratory tests and health care professional visits were the principal drivers of cost, which was 821.2 (1065.6)/patient in the first year after diagnosis. The epidemiology of AA in Spain is comparable with that reported for other countries, being more prevalent among adults. There is a significant burden of comorbidities and cost for patients, with limited use of systemic treatments, suggesting an unmet treatment need in this population.
Assuntos
Alopecia em Áreas , Efeitos Psicossociais da Doença , Custos de Cuidados de Saúde , Humanos , Espanha/epidemiologia , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/economia , Estudos Retrospectivos , Feminino , Masculino , Adulto , Prevalência , Criança , Custos de Cuidados de Saúde/estatística & dados numéricos , Incidência , Pessoa de Meia-Idade , Adolescente , Adulto Jovem , Pré-Escolar , Imunossupressores/uso terapêutico , Imunossupressores/economia , IdosoRESUMO
PURPOSE: The etiology of alopecia areata (AA) in relation to serum lipids remains unclear, thereby prompting our intention to do Mendelian study on this subject. DESIGN: Two-sample Mendelian randomization (MR) analysis was performed in the study. The inverse variance-weighted method was used as the primary method. METHODS: In our study, we integrated a set of 123 single-nucleotide polymorphisms (SNPs) into our analysis. These SNPs have been extensively studied and are known to exhibit associations with serum lipids. We sourced these SNPs from a variety of relevant studies and consortia that specifically focus on lipid-related research, such as the MRC Integrative Epidemiology Unit. These carefully curated SNPs were then utilized as instrumental variables in our analysis, allowing us to explore and evaluate the causal relationships between these genetic variants and serum lipids. By incorporating this comprehensive set of SNPs, we aimed to enhance the precision and robustness of our findings, shedding light on the intricate interplay between genetics and serum lipids. RESULTS: In the MR analysis, a higher total lipid concentration in large low-density lipoprotein (LDL) particles (odds ratio [OR] = 1.502; 95% confidence interval [CI] = 1.086-1.953; p = 0.006), a greater ratio of cholesteryl esters to total lipids in chylomicrons and extremely large very LDL (VLDL) particles (OR = 2.174; 95% CI = 1.300-2.500; p = 0.010), and a greater ratio of cholesterol to total lipids in chylomicrons and extremely large VLDL particles (OR = 2.363;95% CI = 1.556-4.438; p = 0.004), were genetically predicted to be causally associated with an increased risk of AA, while patients with a higher triglyceride to total lipids ratio in chylomicrons and extremely large VLDL particles had a lower risk of AA (OR = 0.481; 95% CI = 0.191-1.270; p = 0.002). CONCLUSION: This study found that serum lipids may be causally implicated in AA.
Assuntos
Alopecia em Áreas , Lipídeos , Análise da Randomização Mendeliana , Polimorfismo de Nucleotídeo Único , Alopecia em Áreas/genética , Alopecia em Áreas/sangue , Alopecia em Áreas/epidemiologia , Humanos , Lipídeos/sangue , Predisposição Genética para Doença/genéticaRESUMO
Alopecia areata (AA), depression, anxiety, and decreased quality of life are highly associated in the literature. It has been noted that there is an increased risk of substance use in those with AA to help cope with the psychological burdens and perceived stigmatization. This study aims to explore the relationship between substance use disorder (SUD) and scarring/non-scarring alopecia using the All of Us database. Of the 9,385 patients with alopecia, 8.4% had SUD of any kind. Multivariable regression revealed that alopecia is a potential protective factor against SUD when controlling for other covariates of significance, with a decreased odds of 0.73. Substance use disorder prevalence was not different between scarring and non-scarring alopecia. This may be the result of patients fearing exacerbation of hair loss, or due to increased mental health and community support in patients with alopecia. Dermatologists and primary care providers should continue to promote psychotherapy and community support to patients whose diagnosis of alopecia has a negative psychosocial impact.
Assuntos
Alopecia em Áreas , Alopecia , Transtornos Relacionados ao Uso de Substâncias , Humanos , Feminino , Masculino , Adulto , Estudos de Casos e Controles , Pessoa de Meia-Idade , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/psicologia , Estados Unidos/epidemiologia , Alopecia/epidemiologia , Alopecia/psicologia , Prevalência , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/psicologia , Alopecia em Áreas/diagnóstico , Alopecia em Áreas/complicações , Qualidade de Vida , Adulto Jovem , Idoso , Cicatriz/psicologia , Cicatriz/epidemiologia , Cicatriz/etiologia , Cicatriz/diagnóstico , AdolescenteRESUMO
Previous observational studies revealed controversy about the effect of circulating antioxidants on risk of alopecia. In the present study, we investigated the causal relationships between diet-derived circulating antioxidants and 2 non-scarring alopecia using Mendelian randomization (MR). Instrumental variables for antioxidants (lycopene, retinol, ascorbate, ß-carotene, α-tocopherol, and γ-tocopherol) were selected from published studies. Data for alopecia areata (AA) and androgenetic alopecia (AGA) was obtained from the FinnGen study project (R9 released in 2023), including 195 cases and 201,019 controls for AGA and 682 cases and 361,140 controls for AA. We used the inverse variance weighted method as the primary MR method. Three additional methods were used as sensitivity analysis to validate the robustness of the results. We found a causal relationship between absolute ß-carotene levels and AGA risk (Pâ =â .039), but not with AA (Pâ =â .283). The results of Wald ratio showed a protective effect of absolute ß-carotene levels against AGA, with per 0.1 ln-transformed ß-carotene being associated with a 76% lower risk of AGA (OR: 0.24, 95% CI: 0.06-0.93). Based on the fixed effects inverse variance weighting results, we found that α-tocopherol was protective against both AGA (Pâ =â .026) and AA (Pâ =â .018). For each unit increase in α-tocopherol, the effects of change in AGA and AA were 0.02 (95% CI: 0.00-0.61) and 0.10 (95% CI: 0.01-0.67), respectively. The results did not reveal any other causal relationships. Our study identified 3 causal associations of antioxidants with the risk of non-scarring alopecia. These results provide new insights into the prevention of non-scarring alopecia through diet.
Assuntos
Alopecia , Antioxidantes , Dieta , Análise da Randomização Mendeliana , beta Caroteno , Humanos , Antioxidantes/metabolismo , beta Caroteno/sangue , Alopecia/genética , Alopecia/sangue , alfa-Tocoferol/sangue , Feminino , Masculino , Alopecia em Áreas/sangue , Alopecia em Áreas/genética , Alopecia em Áreas/epidemiologia , Fatores de RiscoAssuntos
Alopecia em Áreas , Humanos , Alopecia em Áreas/psicologia , Alopecia em Áreas/epidemiologia , Estudos Retrospectivos , Feminino , Masculino , Adulto , Fatores Sexuais , Pessoa de Meia-Idade , Adulto Jovem , Saúde Mental/estatística & dados numéricos , Adolescente , Depressão/epidemiologia , Depressão/psicologia , Depressão/etiologiaAssuntos
Alopecia em Áreas , Isquemia Miocárdica , Humanos , Alopecia em Áreas/epidemiologia , Estados Unidos/epidemiologia , Feminino , Masculino , Adulto , Pessoa de Meia-Idade , Isquemia Miocárdica/epidemiologia , Bases de Dados Factuais/estatística & dados numéricos , Idoso , Transtornos Cerebrovasculares/epidemiologia , Fatores de RiscoRESUMO
Alopecia areata (AA) is an autoimmune disease that develops due to inflammation and causes sudden hair loss. Ithas been observed that family circumstances may contribute to the development of AA. This study aims to assessthe relationship between the development of alopecia areata in children, family functions, and depression andanxiety levels in their parents.Thirty-nine participants diagnosed with AA and 41 healthy controls (HC), agedbetween 8 and 18 years, and their parents participated in the study. The assessment of the children included thecompletion of a socio-demographic data form, the Parenting Style Scale (PSS), and the Revised Children's Anxietyand Depression Scale (RCADS). The parents provided information on a sociodemographic form, the BeckDepression Inventory (BDI), and the Beck Anxiety Inventory (BAI). The children in the control group scoredsignificantly higher on the PSS acceptance/ involvement subscale than those with AA. In the AA group, the numberof authoritative and indulgent (PSS) families was statistically significantly lower than that of the families in the HC,and the number of neglectful families was statistically significantly higher than those of the control group. Totalanxiety and depression t scores (RCADS) were statistically significantly higher in the AA children than in theHC. Our study demonstrates the importance of considering familial factors and parental mental health tounderstand and address alopecia areata in children. Our findings support the psychosomatic component of AA.Implementing comprehensive treatment strategies that target psychological well-being and family dynamics couldprove crucial.
Assuntos
Alopecia em Áreas , Ansiedade , Depressão , Poder Familiar , Humanos , Alopecia em Áreas/psicologia , Alopecia em Áreas/imunologia , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/diagnóstico , Criança , Feminino , Masculino , Adolescente , Poder Familiar/psicologia , Depressão/psicologia , Depressão/epidemiologia , Depressão/diagnóstico , Depressão/etiologia , Ansiedade/psicologia , Ansiedade/epidemiologia , Ansiedade/diagnóstico , Ansiedade/etiologia , Pais/psicologia , Estudos de Casos e ControlesRESUMO
In the field of alopecia areata research, various focuses including risk factors, epidemiology, molecular pathways, and treatment were constantly improving. However, to date, a bibliometric analysis summarizing the research trend is not available to date. The main objective of this study was to provide researchers with an overview of the research trend on alopecia areata in the past two decades. In Web of Science database, screening and extraction of studies related to alopecia areata has been performed. Within studies related to alopecia areata, the most cited 100 studies were appraised and the information of articles, including the citation amounts, keywords and publication types, was extracted for analyses. On average, each study in the top 100 list was cited 104.72 times. Within the top 100 list, the most focused fields were on the management of alopecia areata (34%), molecular mechanisms (28%) and epidemiological issues (23%). Approximately one third of the management-associated studies focused on Janus kinase (JAK) inhibitors (10 studies) and 5 studies focused on the efficacy of corticosteroids for alopecia areata. According to the results of the keyword analysis, JAK inhibitors had become the most mentioned keywords in the field of alopecia areata research since 2016. The top 100 most referenced papers in the field of alopecia areata mostly focused on essential aspects such as treatment options, pathogenesis, risk factors, and comorbidities. The results of the current study could be considered a potential resource for future research and patient care information.
Assuntos
Alopecia em Áreas , Bibliometria , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/tratamento farmacológico , Humanos , Estudos Transversais , Inibidores de Janus Quinases/uso terapêutico , Corticosteroides/uso terapêutico , Pesquisa Biomédica/tendências , Pesquisa Biomédica/estatística & dados numéricosRESUMO
Biologics and Janus kinase (JAK) inhibitors are immunomodulating and immunosuppressing medications utilized to treat atopic dermatitis (AD), psoriasis (PSO), psoriatic arthritis (PsA), and alopecia areata (AA). Special recommendations must be considered when prescribing vaccinations in this population, as the pneumococcal and herpes zoster vaccine are recommended to patients ≥ 19-years-old (rather than ≥ 65-years-old and ≥ 50-years-old as in the general population, respectively), along with a yearly influenza and up to date COVID-19 vaccination. Additionally, TNF-α and JAK-inhibitors may increase the risk of latent Hepatitis B virus (HBV) reactivation among high-risk patients. Prior to prescribing these medications, a quantitative HepB Surface Antibody (HepB SA) test is performed to determine immunity. This study utilized the SlicerDicer function on EPIC Medical Records to search for any patient ≥ 19-years-old prescribed a biologic or JAK inhibitor for AD, PSO, PsA, or AA between 10/2003 and 10/2023 at a large tertiary institution. Vaccination rates among patients on biologics and JAK inhibitors were low, with rates being significantly lower in patients 19-64 years-old, compared to those ≥ 65 years-old for most disease states (p < 0.01). Among AD, PSO/PsA, and AA patients, on average, 9.39% were vaccinated for influenza, 6.76% for herpes zoster, 16.56% for pneumococcal pneumonia, and 63.98% for COVID-19. Only 3.16% of patients were adequately vaccinated for HepB after an abnormal HepB SA test. Here, extremely low rates of vaccination among patients on biologics and JAK inhibitors at our institution were highlighted, emphasizing the imperative need for ensuring vaccination in this group.
Assuntos
Alopecia em Áreas , Artrite Psoriásica , Produtos Biológicos , Dermatite Atópica , Vacinação , Humanos , Pessoa de Meia-Idade , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/imunologia , Dermatite Atópica/epidemiologia , Masculino , Adulto , Feminino , Alopecia em Áreas/imunologia , Alopecia em Áreas/tratamento farmacológico , Alopecia em Áreas/epidemiologia , Produtos Biológicos/uso terapêutico , Produtos Biológicos/efeitos adversos , Idoso , Adulto Jovem , Artrite Psoriásica/tratamento farmacológico , Artrite Psoriásica/imunologia , Vacinação/estatística & dados numéricos , Inibidores de Janus Quinases/uso terapêutico , Psoríase/tratamento farmacológico , Psoríase/imunologia , COVID-19/prevenção & controle , COVID-19/epidemiologia , COVID-19/imunologia , Estudos Retrospectivos , SARS-CoV-2/imunologiaRESUMO
BACKGROUND: Alopecia areata (AA) is an organ-specific autoimmune disease that affects the hair follicles of the scalp and the rest of the body causing hair loss. Due to the unpredictable course of AA and the different degrees of severity of hair loss, only a few well-designed clinical studies with a low number of patients are available. Also, there is no specific cure, but topical and systemic anti-inflammatory and immune system suppressant drugs are used for treatment. The need to create a global registry of AA, comparable and reproducible in all countries, has recently emerged. An Italian multicentric electronic registry is proposed as a model to facilitate and guide the recording of epidemiological and clinical data and to monitor the introduction of new therapies in patients with AA. METHODS: The aim of this study was to evaluate the epidemiological data of patients with AA by collecting detailed information on the course of the disease, associated diseases, concomitant and previous events, and the clinical response to traditional treatments. Estimate the impact on the quality of life of patients. RESULTS: The creation of the National Register of AA has proven to be a valid tool for recording, with a standardized approach, epidemiological data, the trend of AA, response to therapies and quality of life. CONCLUSIONS: AA is confirmed as a difficult hair disease to manage due to its unpredictable course and, in most cases, its chronic-relapsing course, capable of having a significant impact on the quality of life of patients.
Assuntos
Alopecia em Áreas , Sistema de Registros , Alopecia em Áreas/epidemiologia , Humanos , Itália/epidemiologia , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Adolescente , Adulto Jovem , Criança , Qualidade de Vida , Idoso , Pré-EscolarAssuntos
Alopecia em Áreas , Prurigo , Humanos , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/diagnóstico , Alopecia em Áreas/complicações , Prurigo/epidemiologia , Prurigo/diagnóstico , Feminino , Masculino , Adulto , Pessoa de Meia-Idade , Estudos de Coortes , Adulto Jovem , Idoso , AdolescenteRESUMO
Previous studies have proposed alopecia areata (AA) as a potential outcome of COVID-19 infection among autoimmune diseases, yet the findings might be inconclusive and difficult to generalize due to limited sample sizes and evidence levels. Thus, we aimed to investigate in detail the long-term risk of AA following SARS-CoV-2 infection based on large, binational, general population-based cohort studies. Our study investigated the long-term AA risk after SARS-CoV-2 infection by analyzing bi-national, claim-based cohorts in South Korea and Japan: a Korean nationwide cohort (K-COV-N cohort; discovery cohort; total n = 10 027 506) and a Japanese claims-based cohort (JMDC cohort; validation cohort; total n = 12 218 680). AA was identified based on the international classification of diseases 10th revision code (L63) requiring at least three claims within 1 year. After exposure-driven propensity score matching, SARS-CoV-2 infection was associated with an increased risk of incident AA (aHR, 1.66; 95% CI, 1.38-1.99). This increased risk was observed and persisted for up to 6 months. A similar pattern was observed in the validation cohort. As modifiable factors, severe COVID-19 increased the risk of AA, whereas receiving two or more doses of the COVID-19 vaccine before infection decreased the risk of AA. Through a bi-national cohort study in South Korea and Japan, SARS-CoV-2 infection was associated with an elevated risk for incident AA in the aspect of long COVID.
Assuntos
Alopecia em Áreas , COVID-19 , Humanos , Alopecia em Áreas/epidemiologia , COVID-19/epidemiologia , COVID-19/complicações , República da Coreia/epidemiologia , Masculino , Feminino , Japão/epidemiologia , Pessoa de Meia-Idade , Adulto , Estudos de Coortes , Fatores de Risco , Idoso , SARS-CoV-2 , Adulto Jovem , IncidênciaRESUMO
BACKGROUND: This real-world analysis aimed at characterizing patients hospitalized for alopecia areata (AA) in Italy, focusing on comorbidities, treatment patterns and the economic burden for disease management. METHODS: Administrative databases of healthcare entities covering 8.9 million residents were retrospectively browsed to include patients of all ages with hospitalization discharge diagnosis for AA from 2010 to 2020. The population was characterized during the year before the first AA-related hospitalization (index-date) and followed-up for all the available successive period. AA drug prescriptions and treatment discontinuation were analyzed during follow-up. Healthcare costs were also examined. RESULTS: Among 252 patients with AA (mean age 32.1 years, 40.9% males), the most common comorbidities were thyroid disease (22.2%) and hypertension (21.8%), consistent with literature; only 44.4% (112/252) received therapy for AA, more frequently with prednisone, triamcinolone and clobetasol. Treatment discontinuation (no prescriptions during the last trimester) was observed in 86% and 88% of patients, respectively at 12 and 24-month after therapy initiation. Overall healthcare costs were 1715 per patient (rising to 2143 in the presence of comorbidities), mostly driven by hospitalization and drugs expenses. CONCLUSIONS: This first real-world description of hospitalized AA patients in Italy confirmed the youth and female predominance of this population, in line with international data. The large use of corticosteroids over other systemic therapies followed the Italian guidelines, but the high discontinuation rates suggest an unmet need for further treatment options. Lastly, the analysis of healthcare expenses indicated that hospitalizations and drugs were the most impactive cost items.
Assuntos
Alopecia em Áreas , Hospitalização , Humanos , Itália/epidemiologia , Alopecia em Áreas/epidemiologia , Alopecia em Áreas/economia , Alopecia em Áreas/terapia , Masculino , Feminino , Adulto , Estudos Retrospectivos , Hospitalização/economia , Hospitalização/estatística & dados numéricos , Adolescente , Adulto Jovem , Pessoa de Meia-Idade , Criança , Custos de Cuidados de Saúde/estatística & dados numéricos , Comorbidade , Pré-Escolar , Doenças da Glândula Tireoide/epidemiologia , Doenças da Glândula Tireoide/economia , Doenças da Glândula Tireoide/terapia , Hipertensão/epidemiologia , Hipertensão/tratamento farmacológico , Hipertensão/economia , IdosoRESUMO
Alopecia areata (AA) is a kind of alopecia that affects hair follicles and nails. It typically comes with round patches and is a type of nonscarring hair loss. Various therapies are accessible for the management and treatment of AA, including topical, systemic and injectable modalities. It is a very complex type of autoimmune disease and is identified as round patches of hair loss and may occur at any age. This review paper highlights the epidemiology, clinical features, pathogenesis and new treatment options for AA, with a specific emphasis on nanoparticulate drug-delivery systems. By exploring these innovative treatment approaches, researchers aim to enhance the effectiveness and targeted delivery of therapeutic agents, ultimately improving outcomes for individuals living with AA.
Assuntos
Alopecia em Áreas , Doenças Autoimunes , Humanos , Alopecia em Áreas/tratamento farmacológico , Alopecia em Áreas/epidemiologia , Folículo Piloso , Unhas/patologiaRESUMO
BACKGROUND: Alopecia areata (AA) is a chronic autoimmune disease that leads to a high psychiatric, economic and systemic disease burden. A comprehensive understanding of AA epidemiology is essential for evaluating healthcare source utilization; however, a systematic approach to summarizing epidemiological data on AA is lacking. OBJECTIVES: To investigate systematically the global, regional and national incidence and prevalence of AA. METHODS: A structured search was conducted using the databases MEDLINE, Embase, Cochrane Library, Web of Science, SciELO and Korean Journal Database from their date of inception to 4 October 2023. Studies that reported the prevalence or incidence of AA were included. We used a Bayesian hierarchical linear mixed model to analyse prevalence estimates. The primary outcomes of our study were the global, regional and national prevalence of physician-diagnosed AA for the overall population, for adults and for children. The incidence data were summarized descriptively. RESULTS: In total, 88 studies from 28 countries were included in the analysis. The reported incidence of AA tended to be higher in adults aged 19-50â years, and this trend was consistent with its estimated prevalence. The reported prevalence in overall populations tended to be higher in men vs. women. The estimated lifetime prevalence rate of AA was 0.10% [95% credible interval (CrI) 0.03-0.39] in the general population worldwide, 0.12% (95% CrI 0.02-0.52) in adults and 0.03% (95% CrI 0.01-0.12) in children. The estimated prevalence of AA was highest in the Asian region and lowest in the African region. CONCLUSIONS: In this study, 48% of the Global Burden of Disease regions had insufficient data on the prevalence or incidence of AA. Further studies are needed to provide epidemiological information on middle- and low-income countries. Our study may serve as a crucial reference in terms of healthcare policy decisions.
Alopecia areata (AA) is a chronic autoimmune disease that can have both a psychological and physical impact on patients. An understanding of in whom, when and where the disease occurs ('epidemiology') is important to evaluate how healthcare resources are used in AA. There is a lack of analysis of epidemiological data in AA. This study investigated the global, regional and national incidence (the number of new cases in a specific time period) and prevalence (the rate of new cases occurring in a specific population over a specific period of time) of AA by reviewing multiple databases. Studies that reported the prevalence or incidence of AA were analysed. The primary outcomes were the global, regional and national prevalence of AA diagnosed by a doctor for the overall population, for adults only and for children only. Altogether, 88 studies from 28 countries were included in the review. The incidence of AA tended to be higher in adults aged 1950â years, and this trend was consistent with its estimated prevalence. The estimated lifetime prevalence rate (i.e. the proportion of individuals that will be affected) of AA was 0.10% in the general population worldwide, 0.12% in adults and 0.03% in children. The estimated prevalence of AA was highest in the Asian region and lowest in the African region. Overall, we found that 48% of regions did not have enough data on the prevalence or incidence of AA. Further studies are needed to provide epidemiological data on AA, especially in middle- and low-income countries. Our results will help with healthcare policy decisions.
Assuntos
Alopecia em Áreas , Humanos , Alopecia em Áreas/epidemiologia , Prevalência , Incidência , Saúde Global/estatística & dados numéricos , Teorema de Bayes , Distribuição por SexoRESUMO
BACKGROUND: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). OBJECTIVE: The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. METHODS: Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort. Proportions and study size-adjusted incidence rates (IRs) of adverse events (AEs) of interest and laboratory abnormalities are reported. RESULTS: In the placebo-controlled cohort (n = 881; median exposure: 169 days), the proportion of ritlecitinib-treated patients with AEs was 70.2-75.4% across doses versus 69.5% in the placebo group; serious AEs occurred in 0-3.2% versus 1.9% for the placebo. A total of 19 patients permanently discontinued due to AEs (5 while receiving the placebo). In the all-exposure cohort (n = 1294), median ritlecitinib exposure was 624 days [2091.7 total patient-years (PY)]. AEs were reported in 1094 patients (84.5%) and serious AEs in 57 (4.4%); 78 (6.0%) permanently discontinued due to AEs. The most common AEs were headache (17.7%; 11.9/100 PY), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (15.5%; 9.8/100 PY), and nasopharyngitis (12.4%; 8.2/100 PY). There were two deaths (breast cancer and acute respiratory failure/cardiorespiratory arrest). Proportions (IRs) were < 0.1% (0.05/100 PY) for opportunistic infections, 1.5% (0.9/100 PY) for herpes zoster, 0.5% (0.3/100 PY) for malignancies (excluding nonmelanoma skin cancer), and 0.2% (0.1/100 PY) for major adverse cardiovascular events. CONCLUSIONS: Ritlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available). TRIAL REGISTRIES: ClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019).